Deborah Kuk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7888076/publications.pdf

Version: 2024-02-01

52 papers

4,880 citations

35 h-index

46 g-index

223531

52 all docs 52 docs citations

52 times ranked 10436 citing authors

#	Article	IF	CITATIONS
1	Yield of Colonoscopy in Identification of Newly Diagnosed Desmoid-Type Fibromatosis with Underlying Familial Adenomatous Polyposis. Annals of Surgical Oncology, 2019, 26, 765-771.	0.7	12
2	Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated With Better Outcome. Annals of Surgical Oncology, 2017, 24, 1835-1842.	0.7	61
3	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017, 545, 60-65.	13.7	1,280
4	Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2017, 24, 1358-1366.	0.7	86
5	Outcomes after inferior vena cava filter placement in cancer patients diagnosed with pulmonary embolism: risk for recurrent venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2017, 44, 489-493.	1.0	16
6	Size and Location are the Most Important Risk Factors for Malignant Behavior in Resected Solitary Fibrous Tumors. Annals of Surgical Oncology, 2017, 24, 3865-3871.	0.7	69
7	MicroRNA-203 predicts human survival after resection of colorectal liver metastasis. Oncotarget, 2017, 8, 18821-18831.	0.8	19
8	Targeted exome sequencing profiles genetic alterations in leiomyosarcoma. Genes Chromosomes and Cancer, 2016, 55, 124-130.	1.5	38
9	Robotic Liver Resection: A Caseâ€Matched Comparison. World Journal of Surgery, 2016, 40, 1422-1428.	0.8	86
10	The efficacy of antiâ€PDâ€1 agents in acral and mucosal melanoma. Cancer, 2016, 122, 3354-3362.	2.0	236
11	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. Oncologist, 2016, 21, 848-854.	1.9	154
12	Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. Annals of Surgical Oncology, 2016, 23, 410-415.	0.7	87
13	Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget, 2016, 7, 4155-4166.	0.8	51
14	Near universal detection of alterations in <scp><i>CTNNB1</i></scp> and <scp>Wnt</scp> pathway regulators in desmoidâ€type fibromatosis by wholeâ€exome sequencing and genomic analysis. Genes Chromosomes and Cancer, 2015, 54, 606-615.	1.5	138
15	Soft tissue sarcoma of the head & neck: Nomogram validation and analysis of staging systems. Journal of Surgical Oncology, 2015, 111, 690-695.	0.8	19
16	Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma. Oncology, 2015, 89, 205-214.	0.9	38
17	Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. British Journal of Cancer, 2015, 113, 1658-1665.	2.9	15
18	Bone Marrow Minimal Residual Disease Was an Early Response Marker and a Consistent Independent Predictor of Survival After Anti-GD2 Immunotherapy. Journal of Clinical Oncology, 2015, 33, 755-763.	0.8	40

#	Article	IF	CITATIONS
19	Osteochondroma in longâ€term survivors of highâ€risk neuroblastoma. Cancer, 2015, 121, 2090-2096.	2.0	15
20	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human Pathology, 2015, 46, 357-365.	1.1	252
21	Pediatric Bone Sarcoma: Diagnostic Performance of ¹⁸ F-FDG PET/CT Versus Conventional Imaging for Initial Staging and Follow-Up. American Journal of Roentgenology, 2015, 204, 153-160.	1.0	97
22	Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G _{D2} immunotherapy and isotretinoin: a prospective Phase II study. Oncolmmunology, 2015, 4, e1016704.	2.1	52
23	Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. European Journal of Cancer, 2015, 51, 2413-2422.	1.3	79
24	Autologous Transplant, and Not ATO Alone, Remains the Preferred Therapy for Relapsed APL: A Report from the CIBMTR, EBMT and Two Specialized Centers. Blood, 2015, 126, 928-928.	0.6	0
25	Outcomes of Inferior Vena Cava Filter Placement in a Large Population of Cancer Patients Diagnosed with Pulmonary Embolism: Risk for Recurrent Venous Thromboembolism, Survival, and Filter-Related Complications. Blood, 2015, 126, 1112-1112.	0.6	0
26	Bone Metastases in Castration-Resistant Prostate Cancer: Associations between Morphologic CT Patterns, Glycolytic Activity, and Androgen Receptor Expression on PET and Overall Survival. Radiology, 2014, 271, 220-229.	3.6	88
27	Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes. Cancer Immunology Research, 2014, 2, 812-821.	1.6	122
28	Key role for myeloid cells: Phase II results of antiâ€G _{D2} antibody 3F8 plus granulocyteâ€macrophage colonyâ€stimulating factor for chemoresistant osteomedullary neuroblastoma. International Journal of Cancer, 2014, 135, 2199-2205.	2.3	77
29	Analysis of Outcomes in Extraskeletal Osteosarcoma. Journal of Bone and Joint Surgery - Series A, 2014, 96, e2.	1.4	50
30	International Multi-institutional Management and Outcome of Melanoma Patients with Positive Sentinel Lymph Nodes in More than One Nodal Basin. Annals of Surgical Oncology, 2014, 21, 4324-4329.	0.7	13
31	Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma. American Journal of Surgical Pathology, 2014, 38, 1118-1127.	2.1	131
32	Stage-Stratified Prognosis of Signet Ring Cell Histology in Patients Undergoing Curative Resection for Gastric Adenocarcinoma. Annals of Surgical Oncology, 2014, 21, 1678-1685.	0.7	103
33	Prognostic Significance of the Highest Peripancreatic Lymph Node in Biliary Tract Adenocarcinoma. Annals of Surgical Oncology, 2014, 21, 979-985.	0.7	9
34	Comparison of Local Recurrence With Conventional and Intensity-Modulated Radiation Therapy for Primary Soft-Tissue Sarcomas of the Extremity. Journal of Clinical Oncology, 2014, 32, 3236-3241.	0.8	125
35	Observation After a Positive Sentinel Lymph Node Biopsy in Patients with Melanoma. Annals of Surgical Oncology, 2014, 21, 3117-3123.	0.7	63
36	Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunology Research, 2014, 2, 127-132.	1.6	122

3

#	Article	IF	CITATIONS
37	Prognostic Aspects of DCE-MRI in Recurrent Rectal Cancer. European Radiology, 2013, 23, 3336-3344.	2.3	17
38	Model selection in competing risks regression. Statistics in Medicine, 2013, 32, 3077-3088.	0.8	105
39	Short-term Androgen-Deprivation Therapy Improves Prostate Cancer-Specific Mortality in Intermediate-Risk Prostate Cancer Patients Undergoing Dose-Escalated External Beam Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1012-1017.	0.4	55
40	High-risk features in radiation-associated breast angiosarcomas. British Journal of Cancer, 2013, 109, 2340-2346.	2.9	60
41	T Cell–Depleted Stem Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia: Long-Term Survival for Patients in First Complete Remission with a Decreased Risk of Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2013, 19, 208-213.	2.0	41
42	Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma Journal of Clinical Oncology, 2013, 31, 9052-9052.	0.8	25
43	Poor prognostic features in angiosarcoma: A single institution retrospective study of 324 patients Journal of Clinical Oncology, 2013, 31, 10580-10580.	0.8	0
44	Observation after a positive sentinel lymph node biopsy in patients with melanoma Journal of Clinical Oncology, 2013, 31, 9033-9033.	0.8	0
45	Association of perioperative radiation therapy with outcome in 204 patients with primary retroperitoneal sarcoma: A two-institution study Journal of Clinical Oncology, 2013, 31, 10520-10520.	0.8	0
46	Multiparameter Flow Cytometry For Detection Of Minimal Residual Disease In Multiple Myeloma After T-Cell Depleted Allogeneic Stem Cell Transplant. Blood, 2013, 122, 4647-4647.	0.6	0
47	Secondary cancers after intensityâ€modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and causeâ€specific survival outcomes according to the initial treatment intervention. BJU International, 2012, 110, 1696-1701.	1.3	85
48	Is Port Site Resection Necessary in the Surgical Management of Gallbladder Cancer?. Annals of Surgical Oncology, 2012, 19, 409-417.	0.7	118
49	Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. European Radiology, 2012, 22, 821-831.	2.3	121
50	Poor Graft Function in Recipients of T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplants (HSCT) Is Mostly Related to Viral Infections and Anti-Viral Therapy Blood, 2012, 120, 3147-3147.	0.6	5
51	Integrated NY-ESO-1 antibody and CD8 ⁺ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16723-16728.	3.3	310
52	Neoadjuvant and Adjuvant Chemotherapy in Resected Pulmonary Large Cell Neuroendocrine Carcinomas: A Single Institution Experience. Annals of Thoracic Surgery, 2011, 92, 1180-1187.	0.7	95